Efficacy and Safety of Once-Daily Vilanterol/Fluticasone Furoate MDI in Persistent Asthma: Phase 3 OD-INHALE study
Conclusion: Once daily VI/FF pMDI was non-inferior to twice daily FOR/FP pMDI in patients with persistent asthma.PMID:38488853 | DOI:10.1080/02770903.2024.2330485 (Source: Journal of Asthma)
Source: Journal of Asthma - March 15, 2024 Category: Respiratory Medicine Authors: Avdhesh Kumar Manish Kumar Jain Vijaykumar Bhagwan Barge Raghumanda Sunil Kumar Neeraj Gupta Harendra Yadav Amitava Pal Vivek Eknath Redkar Asish Mondal Rahul Kumar Rathore Pavankumar Daultani Ashok Jaiswal Ravi T Mehta Source Type: research
Comparing Budesonide and Fluticasone Propionate in Children with Moderate to Severe Asthma: A Pilot Randomized Controlled Trial
This study aimed to compare the effects of fluticasone propionate (FP) and budesonide (Bud) on the clinical symptoms and control of asthma in children with moderate to severe asthma. In this open-label study, children with moderate to severe asthma were randomly selected to receive either FP 250 mcg or Bud 400 mcg for 3 months. Asthma control test scores were measured in both groups monthly. The clinical symptoms, drug adherence, and rescue medication were also evaluated. A total of 50 patients with ages between 4 and 7 years old were included in the study (25 cases received Bud and 25 cases received FP). Asthma control te...
Source: Iranian Journal of Allergy, Asthma and Immunology - March 13, 2024 Category: Allergy & Immunology Authors: Mansour Sadeghzadeh Parisa Khoshnevisasl Akefeh Ahmadiafshar Nima Motamed Azadeh Pourmarjani Source Type: research
Comparing Budesonide and Fluticasone Propionate in Children with Moderate to Severe Asthma: A Pilot Randomized Controlled Trial
This study aimed to compare the effects of fluticasone propionate (FP) and budesonide (Bud) on the clinical symptoms and control of asthma in children with moderate to severe asthma. In this open-label study, children with moderate to severe asthma were randomly selected to receive either FP 250 mcg or Bud 400 mcg for 3 months. Asthma control test scores were measured in both groups monthly. The clinical symptoms, drug adherence, and rescue medication were also evaluated. A total of 50 patients with ages between 4 and 7 years old were included in the study (25 cases received Bud and 25 cases received FP). Asthma control te...
Source: Iranian Journal of Allergy, Asthma and Immunology - March 13, 2024 Category: Allergy & Immunology Authors: Mansour Sadeghzadeh Parisa Khoshnevisasl Akefeh Ahmadiafshar Nima Motamed Azadeh Pourmarjani Source Type: research
Regional lung targeting with a fluticasone/salmeterol aerosol using a bolus breath hold method of the PreciseInhale ® system: A first evaluation in humans
CONCLUSIONS: When one inhaler dose was administered via the PI system, the absorbed dose, expressed as AUC24, was approximately twice as high and the CV was less than half, compared to direct inhalation from the same pMDI. Bolus breath hold targeting of drugs from the same aerosol mixture to the peripheral lung and the central airways showed a difference in their appearance in the systemic circulation. Normalized to the same deposited dose, SMX had a 57% higher Cmax in the peripheral lung compared to the central airways. However, from 6 to 24 h after dosing the systemic concentrations of SMX from both regions were quite si...
Source: European Journal of Pharmaceutical Sciences - March 9, 2024 Category: Drugs & Pharmacology Authors: Per Gerde Carl-Olof Sj öberg Helen B äckroos Joakim Englund Marit Wangheim Helena Litorp Source Type: research
Regional lung targeting with a fluticasone/salmeterol aerosol using a bolus breath hold method of the PreciseInhale ® system: A first evaluation in humans
CONCLUSIONS: When one inhaler dose was administered via the PI system, the absorbed dose, expressed as AUC24, was approximately twice as high and the CV was less than half, compared to direct inhalation from the same pMDI. Bolus breath hold targeting of drugs from the same aerosol mixture to the peripheral lung and the central airways showed a difference in their appearance in the systemic circulation. Normalized to the same deposited dose, SMX had a 57% higher Cmax in the peripheral lung compared to the central airways. However, from 6 to 24 h after dosing the systemic concentrations of SMX from both regions were quite si...
Source: European Journal of Pharmaceutical Sciences - March 9, 2024 Category: Drugs & Pharmacology Authors: Per Gerde Carl-Olof Sj öberg Helen B äckroos Joakim Englund Marit Wangheim Helena Litorp Source Type: research
Effect of Individual Patient Characteristics and Treatment Choices on Reliever Medication Use in Moderate-Severe Asthma: A Poisson Analysis of Randomised Clinical Trials
ConclusionsThe availability of individual-level patient data in conjunction with a parametric approach enabled the characterisation of interindividual differences in the patterns of reliever use in patients with moderate-severe asthma. Taken together, individual demographic and clinical characteristics, as well as exacerbation history, can be considered an indicator of the degree of asthma control. High SABA reliever use suggests suboptimal clinical management of patients on maintenance therapy. (Source: Advances in Therapy)
Source: Advances in Therapy - February 1, 2024 Category: Drugs & Pharmacology Source Type: research
Fluticasone Furoate versus Fluticasone Propionate/Azelastine in Moderate-to-Severe Persistent Perennial Allergic Rhinitis from Thai Adult chronic Rhinitis prospective Cohort (TARhiC)
According to the 2-week randomized trials in patients with seasonal allergic rhinitis, intranasal corticosteroid (INCS)/intranasal antihistamine was more effective than INCS monotherapy. However, studies longer than 2-week duration in perennial allergic rhinitis (PAR) comparing their efficacy are limited. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Piyaporn Chokevittaya, Chamard Wongsa, Irin Vichara-Anont, Thanachit Krikeerati, Mongkhon Sompornrattanaphan, Kawita Atipas, Dichapong Kanjanawasee, Triphoom Suwanwech, Pongsakorn Tantilipikorn, Torpong Thongngarm Source Type: research
Dupilumab suppresses relapsing chronic eosinophilic pneumonia with severe asthma
Nagoya J Med Sci. 2023 Nov;85(4):857-865. doi: 10.18999/nagjms.85.4.857.ABSTRACTDupilumab-induced hypereosinophilia is mediated by blockade of the IL-4/IL-13 pathway, which reduces eosinophil migration from peripheral blood. The increase in peripheral blood eosinophils may lead to chronic eosinophilic pneumonia (CEP) and/or eosinophilic granulomatosis with polyangiitis, but a direct causal connection between dupilumab and eosinophilic lung diseases has not been established. A 33-year-old Japanese woman with bronchial asthma since age three was treated with fluticasone propionate plus salmeterol twice daily after several as...
Source: Nagoya Journal of Medical Science - December 29, 2023 Category: International Medicine & Public Health Authors: Nami Masumoto Chiyako Oshikata Ryo Nakadegawa Yuto Motobayashi Reeko Osada Saki Manabe Takeshi Kaneko Naomi Tsurikisawa Source Type: research
